Approval was based on results from the Phase III inMIND trial, which demonstrated a statistically significant and clinically ...

The decision to advance prasinezumab to Phase III was based on results from the Phase IIb PADOVA trial, which demonstrated ...

With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales ...

FDA approves first targeted therapy for bullous pemphigoid (BP): Dupixent (dupilumab) becomes the first and only targeted ...

The traditional approach to trial management relies on a mix of solutions that often become siloed and difficult to integrate ...

Harliku becomes the first FDA-approved treatment for alkaptonuria, indicated to reduce homogentisic acid levels in affected ...

A look at China's emergence as a hub for novel treatment pursuits—and ways international investors can best capitalize on the favorable research trajectory.

The investigational MRI contrast agent, gadoquatrane, is designed to deliver effective imaging at a significantly reduced ...

Approval of first twice-yearly HIV pre-exposure prophylaxis was based on results from the Phase III PURPOSE 1 and PURPOSE 2 ...

Jim Weiss, founder and chairman of Real Chemistry, and the 2025 HBA Honorable Mentor, discusses the foundation and journey ...

Results from the Phase III TEMPLE trial show that patients administered Qulipta (atogepant) experienced significantly fewer ...

With acquisition of Verve Therapeutics, Eli Lilly aims to advance next-generation cardiovascular care through one-time gene ...